ExThera Medical Corporation, a Martinez, CA-based developer of innovative blood filtering technology, closed a $15.3m Series B financing round.
The round was led by new investor Fresenius Medical Care Ventures with participation from existing investors and the conversion of a convertible note.
The company intends to use the funds for European and U.S. clinical trials and regulatory approvals, and scaling manufacturing of its therapeutic blood filter.
Led by Robert Ward, CEO, ExThera Medical, ExThera advances proprietary a blood filter (Seraph® Microbind® Affinity Blood Filter), a device capable of capturing and removing a broad range of sepsis-causing bacteria, viruses, toxins and pro-inflammatory cytokines from whole blood. Validated in preclinical studies, the filter is currently under evaluation in a first-in-man clinical trial in Europe.
ExThera’s immediate focus is on therapeutic applications in high-risk populations such as patients undergoing dialysis while potential applications include treatment for drug-resistant “superbugs” and the purification of blood for use by blood banks.